Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.40 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.35 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.35 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.35 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.35 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791820 | 0.87 | DRD2 (0.41) | DRD2BRD4DRD3SUV39H2 | |
| SCHEMBL6794238 | 0.83 | DRD2 (0.41) | DRD2BRD4DRD3SUV39H2 | |
| SCHEMBL6786895 | 0.83 | DYRK1A (0.43) | DRD2BRD4 | |
| SCHEMBL6791852 | 0.82 | SUV39H2 (0.41) | DRD2ABL1SRCBRD4SUV39H2 | |
| SCHEMBL6792526 | 0.80 | DRD2 (0.39) | DRD2ABL1SRCBRD4DRD3 | |
| SCHEMBL6788891 | 0.79 | DRD2 (0.39) | DRD2BRD4FAAHDRD3SUV39H2 | |
| SCHEMBL6793501 | 0.79 | DRD2 (0.39) | DRD2BRD4DRD3 | |
| SCHEMBL6793140 | 0.79 | DRD2 (0.38) | DRD2ABL1SRCBRD4SUV39H2 | |
| SCHEMBL6792678 | 0.77 | BRD4 (0.37) | DRD2BRD4SUV39H2 | |
| SCHEMBL6792702 | 0.76 | DRD2 (0.42) | DRD2BRD4FAAHDRD3SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | DRD2 4396/4885CACNB4 3909/4885CACNA1A 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.